

ENCELIN OD 100/ TORGLIP OD 100

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.

Abbreviated Prescribing information for ENCELIN OD 100/ TORGLIP OD 100

[Vildagliptin Sustained Release Tablets I.P. 100mg]

Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

DOSAGE AND ADMINISTRATION: The recommended daily dose of vildagliptin is 100 mg. Vildagliptin can be administered with or without a meal.

CONTRAINDICATION: • Hypersensitivity to the active substance or to any of the excipients.

WARNINGS & PRECAUTIONS: Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, Renal and Hepatic impairment, Liver enzyme monitoring, Cardiac failure, Skin disorders, Acute pancreatitis, Hypoglycaemia.

DRUG INTERACTION: Combination with pioglitazone, metformin and glyburide, Digoxin (Pgp substrate), warfarin (CYP2C9 substrate), with amlodipine, ramipril, valsartan or simvastatin with ACE-inhibitors.

ADVERSE REACTIONS: Nasopharyngitis, upper respiratory tract infection, dizziness, headache, tremor, vision blurred, constipation, nausea, gastro-oesophageal reflux disease, diarrhoea, abdominal pain, vomiting, hyperhidrosis, rash, pruritis, dermatitis, arthralgia, myalgia, hypoglycemia, flatulence, pancreatitis, hepatitis, exfoliative and bullous skin lesion, including bullous pemphigoid, cutaneous vasculitis, urticaria, erectile dysfunction, asthenia, oedema peripheral, fatigue, chills, abnormal liver function tests, weight increase.

Marketed by:



TORRENT PHARMACEUTICALS LTD.

IN/ENCELIN OD 100 /TORGLIP OD 100 mg/Jan-2026/03/ABPI

(Additional information is available on request)